scispace - formally typeset
Search or ask a question
Author

Márcio Jansen de Oliveira Figueiredo

Bio: Márcio Jansen de Oliveira Figueiredo is an academic researcher from State University of Campinas. The author has contributed to research in topics: Atrial fibrillation & Medicine. The author has an hindex of 12, co-authored 27 publications receiving 606 citations.

Papers
More filters
Journal ArticleDOI
01 Jun 2017-Europace
TL;DR: A Task Force was convened with the remit to comprehensively review the available evidence to publish a joint consensus document on hypertension and cardiac arrhythmias, and to provide up-to-date consensus recommendations for use in clinical practice.
Abstract: Hypertension is a common cardiovascular risk factor leading to heart failure (HF), coronary artery disease, stroke, peripheral artery disease and chronic renal insufficiency. Hypertensive heart disease can manifest as many cardiac arrhythmias, most commonly being atrial fibrillation (AF). Both supraventricular and ventricular arrhythmias may occur in hypertensive patients, especially in those with left ventricular hypertrophy (LVH) or HF. Also, some of the antihypertensive drugs commonly used to reduce blood pressure, such as thiazide diuretics, may result in electrolyte abnormalities (e.g. hypokalaemia, hypomagnesemia), further contributing to arrhythmias, whereas effective control of blood pressure may prevent the development of the arrhythmias such as AF. In recognizing this close relationship between hypertension and arrhythmias, the European Heart Rhythm Association (EHRA) and the European Society of Cardiology (ESC) Council on Hypertension convened a Task Force, with representation from the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE), with the remit to comprehensively review the available evidence to publish a joint consensus document on hypertension and cardiac arrhythmias, and to provide up-to-date consensus recommendations for use in clinical practice. The ultimate judgment regarding care of a particular patient must be made by the healthcare provider and the patient in light of all of the circumstances presented by that patient.

138 citations

Journal ArticleDOI
01 Feb 2017-Europace
TL;DR: By implementing AF risk reduction strategies aiming at risk factors such as obesity, hypertension, diabetes, and obstructive sleep apnoea (OSA), which are interrelated, this work impact upon the escalating escalating risk of developing AF.
Abstract: ACEI, : angiotensin converting enzyme inhibitors AF, : atrial fibrillation ARB, : angiotensin receptor blockers AVNRT, : atrioventricular nodal re-entry tachycardia BMI, : body mass index CHADS2, : cardiac failure, hypertension, age, diabetes, stroke (doubled) CHA2DS2-VASc, : congestive heart failure or left ventricular dysfunction, hypertension, age ≥75 (doubled), diabetes, stroke/transient ischaemic attack (doubled)-vascular disease, age 65–74, sex category (female) CI, : confidence interval FU, : follow-up HR, : hazard ratio HDL, : high-density lipoprotein cholesterol ICD, : implantable cardioverter defibrillators LA, : left atrium LDL, : low-density lipoprotein cholesterol LV, : left ventricle NOAC, : non-VKA oral anticoagulant OAC, : oral anticoagulation OR, : odds ratio OSA, : obstructive sleep apnoea n 3-PUFA, : ω-3 polyunsaturated fatty acids RAAS, : renin–angiotensin–aldosterone system RR, : relative risk SBP, : systolic blood pressure SAMe-TT2R2, : sex (female), age (<60 years), medical history, treatment (interacting drugs, eg amiodarone for rhythm control), tobacco use (within 2 years) (doubled), Race (non-Caucasian) (doubled) SVT, : supraventricular tachyarrhythmia VKA, : vitamin K antagonist Atrial fibrillation (AF) is an important and highly prevalent arrhythmia, which is associated with significantly increased morbidity and mortality, including a four- to five-fold increased risk for stroke,1,2 a two-fold increased risk for dementia,3,4 a three-fold risk for heart failure,2 a two-fold increased risk for myocardial infarction,5,6 and a 40–90% increased risk for overall mortality2,7 The constantly increasing number of AF patients and recognition of increased morbidity, mortality, impaired quality of life, safety issues, and side effects of rhythm control strategies with antiarrhythmic drugs, and high healthcare costs associated with AF have spurred numerous investigations to develop more effective treatments for AF and its complications8 Although AF treatment has been studied extensively, AF prevention has received relatively little attention, while it has paramount importance in the prevention of morbidity and mortality, and complications associated with arrhythmia and its treatment Current evidence shows a clear association between the presence of modifiable risk factors and the risk of developing AF By implementing AF risk reduction strategies aiming at risk factors such as obesity, hypertension, diabetes, and obstructive sleep apnoea (OSA), which are interrelated, we impact upon the escalating …

105 citations

Journal ArticleDOI
TL;DR: It is observed that mice with chronic AMPK activation, resulting from mutation of the AMPK γ2 subunit, exhibit ghrelin signaling-dependent hyperphagia, obesity, and impaired pancreatic islet insulin secretion.

86 citations

Journal ArticleDOI
TL;DR: This expert consensus statement task force was set down to raise awareness of using the right risk assessment tool for a given outcome in a given population, and to provide physicians with practical proposals that may lead to rational and evidence-based risk assessment and improvement of patient care in this regard.

62 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only and no commercial use is authorized.
Abstract: Supplementary Table 9, column 'Edoxaban', row 'eGFR category', '95 mL/min' (page 15). The cell should be coloured green instead of yellow. It should also read "60 mg"instead of "60 mg (use with caution in 'supranormal' renal function)."In the above-indicated cell, a footnote has also been added to state: "Edoxaban should be used in patients with high creatinine clearance only after a careful evaluation of the individual thromboembolic and bleeding risk."Supplementary Table 9, column 'Edoxaban', row 'Dose reduction in selected patients' (page 16). The cell should read "Edoxaban 60 mg reduced to 30 mg once daily if any of the following: creatinine clearance 15-50 mL/min, body weight <60 kg, concomitant use of dronedarone, erythromycin, ciclosporine or ketokonazole"instead of "Edoxaban 60 mg reduced to 30 mg once daily, and edoxaban 30 mg reduced to 15mg once daily, if any of the following: creatinine clearance of 30-50 mL/min, body weight <60 kg, concomitant us of verapamil or quinidine or dronedarone."

4,285 citations

Journal ArticleDOI
TL;DR: De Backer et al. as mentioned in this paper developed the ESC Guidelines for the ESC Review Co-ordinator, which are used for the evaluation of the ESC review process and the review process.
Abstract: Document reviewers: Guy De Backer (ESC Review Co-ordinator) (Belgium), Anthony M. Heagerty (ESH Review Co-ordinator) (UK), Stefan Agewall (Norway), Murielle Bochud (Switzerland), Claudio Borghi (Italy), Pierre Boutouyrie (France), Jana Brguljan (Slovenia), Hector Bueno (Spain), Enrico G. Caiani (Italy), Bo Carlberg (Sweden), Neil Chapman (UK), Renata Cifkova (Czech Republic), John G. F. Cleland (UK), Jean-Philippe Collet (France), Ioan Mircea Coman (Romania), Peter W. de Leeuw (The Netherlands), Victoria Delgado (The Netherlands), Paul Dendale (Belgium), Hans-Christoph Diener (Germany), Maria Dorobantu (Romania), Robert Fagard (Belgium), Csaba Farsang (Hungary), Marc Ferrini (France), Ian M. Graham (Ireland), Guido Grassi (Italy), Hermann Haller (Germany), F. D. Richard Hobbs (UK), Bojan Jelakovic (Croatia), Catriona Jennings (UK), Hugo A. Katus (Germany), Abraham A. Kroon (The Netherlands), Christophe Leclercq (France), Dragan Lovic (Serbia), Empar Lurbe (Spain), Athanasios J. Manolis (Greece), Theresa A. McDonagh (UK), Franz Messerli (Switzerland), Maria Lorenza Muiesan (Italy), Uwe Nixdorff (Germany), Michael Hecht Olsen (Denmark), Gianfranco Parati (Italy), Joep Perk (Sweden), Massimo Francesco Piepoli (Italy), Jorge Polonia (Portugal), Piotr Ponikowski (Poland), Dimitrios J. Richter (Greece), Stefano F. Rimoldi (Switzerland), Marco Roffi (Switzerland), Naveed Sattar (UK), Petar M. Seferovic (Serbia), Iain A. Simpson (UK), Miguel Sousa-Uva (Portugal), Alice V. Stanton (Ireland), Philippe van de Borne (Belgium), Panos Vardas (Greece), Massimo Volpe (Italy), Sven Wassmann (Germany), Stephan Windecker (Switzerland), Jose Luis Zamorano (Spain).The disclosure forms of all experts involved in the development of these Guidelines are available on the ESC website www.escardio.org/guidelines.

1,781 citations

Journal ArticleDOI
Frank L.J. Visseren, François Mach, Yvo M. Smulders, David Carballo, Konstantinos C. Koskinas, Maria Bäck, Athanase Benetos, Alessandro Biffi, José-Manuel Boavida1, Davide Capodanno, Bernard Cosyns, Carolyn Crawford, Constantinos H. Davos, Ileana Desormais, Emanuele Di Angelantonio, Oscar H. Franco, Sigrun Halvorsen, FD Richard Hobbs, Monika Hollander, Ewa A. Jankowska, Matthias Michal, Simona Sacco, Naveed Sattar, Lale Tokgozoglu, Serena Tonstad, Konstantinos P Tsioufis2, Ineke van Dis, Isabelle C. Van Gelder, Christoph Wanner3, Bryan Williams, Guy De Backer, Vera Regitz-Zagrosek, Anne Hege Aamodt, Magdy Abdelhamid, Victor Aboyans, Christian Albus, Riccardo Asteggiano, Magnus Bäck, Michael A. Borger, Carlos Brotons, Jelena Čelutkienė, Renata Cifkova, Maja Čikeš, Francesco Cosentino, Nikolaos Dagres, Tine De Backer, Dirk De Bacquer, Victoria Delgado, Hester Den Ruijter, Paul Dendale, Heinz Drexel, Volkmar Falk, Laurent Fauchier, Brian A. Ference, Jean Ferrières, Marc Ferrini4, Miles Fisher4, Danilo Fliser3, Zlatko Fras, Dan Gaita, Simona Giampaoli, Stephan Gielen, Ian D. Graham, Catriona Jennings, Torben Jørgensen, Alexandra Kautzky-Willer, Maryam Kavousi, Wolfgang Koenig, Aleksandra Konradi, Dipak Kotecha, Ulf Landmesser, Madalena Lettino, Basil S. Lewis, Aleš Linhart, Maja-Lisa Løchen1, Konstantinos Makrilakis1, Giuseppe Mancia2, Pedro Marques-Vidal, John W. McEvoy, Paul McGreavy, Béla Merkely, Lis Neubeck, Jens Cosedis Nielsen, Joep Perk, Steffen E. Petersen, Anna Sonia Petronio, Massimo F Piepoli, Nana Pogosova, Eva Prescott, Kausik K. Ray, Zeljko Reiner, Dimitrios J. Richter, Lars Rydén, Evgeny Shlyakhto, Marta Sitges, Miguel Sousa-Uva, Isabella Sudano, Monica Tiberi, Rhian M. Touyz, Andrea Ungar, W. M. Monique Verschuren, Olov Wiklund, David A. Wood, José Luis Zamorano, Carolyn A Crawford, Oscar H Franco Duran 

1,650 citations

Journal ArticleDOI
TL;DR: This 2017 Consensus Statement is to provide a state-of-the-art review of the field of catheter and surgical ablation of AF and to report the findings of a writing group, convened by these five international societies.

1,626 citations